187 related articles for article (PubMed ID: 35290915)
1. ACCELERATE - Five years accelerating cancer drug development for children and adolescents.
Pearson ADJ; Weiner SL; Adamson PC; Karres D; Reaman G; Rousseau R; Blanc P; Norga K; Skolnik J; Kearns P; Scobie N; Barry E; Marshall LV; Knox L; Caron H; Wariabharaj D; Pappo A; DuBois SG; Gore L; Kieran M; Weigel B; Fox E; Nysom K; de Rojas T; Vassal G
Eur J Cancer; 2022 May; 166():145-164. PubMed ID: 35290915
[TBL] [Abstract][Full Text] [Related]
2. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ; Zwaan CM; Kolb EA; Karres D; Guillot J; Kim SY; Marshall L; Tasian SK; Smith M; Cooper T; Adamson PC; Barry E; Benettaib B; Binlich F; Borgman A; Brivio E; Capdeville R; Delgado D; Faller D; Fogelstrand L; Fraenkel PG; Hasle H; Heenen D; Kaspers G; Kieran M; Klusmann JH; Lesa G; Ligas F; Mappa S; Mohamed H; Moore A; Morris J; Nottage K; Reinhardt D; Scobie N; Simko S; Winkler T; Norga K; Reaman G; Vassal G
Eur J Cancer; 2020 Sep; 136():116-129. PubMed ID: 32688206
[TBL] [Abstract][Full Text] [Related]
3. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
[TBL] [Abstract][Full Text] [Related]
4. Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development.
Pearson ADJ; de Rojas T; Karres D; Reaman G; Scobie N; Fox E; Lesa G; Ligas F; Norga K; Nysom K; Pappo A; Weigel B; Weiner SL; Vassal G
J Natl Cancer Inst; 2024 Feb; 116(2):200-207. PubMed ID: 37975877
[TBL] [Abstract][Full Text] [Related]
5. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
6. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
7. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Gaspar N; Janeway K; Campbell-Hewson Q; Lawlor ER; Copland C; Karres D; Norga K; Benzaghou F; Weiner S; Weigel B; Weiss AR; Strauss SJ; Smith M; Setty BA; Seibel N; Scobie N; Pappo A; Okpara CE; Nysom K; McDonough J; Marshall LV; Ludwinski D; Ligas F; Lesa G; Knudsen S; Kauh J; Hsieh A; Heenen D; Hawkins DS; Graham A; Garmey E; DuBois SG; Fox E; Donoghue M; de Rojas T; Chung J; Casanova M; Brennan B; Bishop M; Buenger V; Reaman G; Vassal G
Eur J Cancer; 2022 Sep; 173():71-90. PubMed ID: 35863108
[TBL] [Abstract][Full Text] [Related]
8. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ; Federico S; Gatz SA; Ortiz M; Lesa G; Scobie N; Gounaris I; Weiner SL; Weigel B; Unger TJ; Stewart E; Smith M; Slotkin EK; Reaman G; Pappo A; Nysom K; Norga K; McDonough J; Marshall LV; Ludwinski D; Ligas F; Karres D; Kool M; Horner TJ; Henssen A; Heenen D; Hawkins DS; Gore L; Bender JG; Galluzzo S; Fox E; de Rojas T; Davies BR; Chakrabarti J; Carmichael J; Bradford D; Blanc P; Bernardi R; Benchetrit S; Akindele K; Vassal G
Eur J Cancer; 2023 Sep; 190():112950. PubMed ID: 37441939
[TBL] [Abstract][Full Text] [Related]
9. Implementation of mechanism of action biology-driven early drug development for children with cancer.
Pearson AD; Herold R; Rousseau R; Copland C; Bradley-Garelik B; Binner D; Capdeville R; Caron H; Carleer J; Chesler L; Geoerger B; Kearns P; Marshall LV; Pfister SM; Schleiermacher G; Skolnik J; Spadoni C; Sterba J; van den Berg H; Uttenreuther-Fischer M; Witt O; Norga K; Vassal G;
Eur J Cancer; 2016 Jul; 62():124-31. PubMed ID: 27258969
[TBL] [Abstract][Full Text] [Related]
10. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Allen C; Fangusaro J; Hutter C; Witt O; Weiner S; Reaman G; Russo M; Bandopadhayay P; Ahsan S; Barone A; Barry E; de Rojas T; Fisher M; Fox E; Bender JG; Gore L; Hargrave D; Hawkins D; Kreider B; Langseth AJ; Lesa G; Ligas F; Marotti M; Marshall LV; Nasri K; Norga K; Nysom K; Pappo A; Rossato G; Scobie N; Smith M; Stieglitz E; Weigel B; Weinstein A; Viana R; Karres D; Vassal G
Eur J Cancer; 2022 Dec; 177():120-142. PubMed ID: 36335782
[TBL] [Abstract][Full Text] [Related]
11. Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer - An ACCELERATE Multistakeholder Consensus.
de Rojas T; Chiodin D; Pearson ADJ; Heenen D; Adamson P; Caron H; Vassal G
Clin Pharmacol Ther; 2024 Jan; 115(1):36-41. PubMed ID: 37885401
[TBL] [Abstract][Full Text] [Related]
12. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.
Pearson ADJ; Scobie N; Norga K; Ligas F; Chiodin D; Burke A; Minard-Colin V; Adamson P; Marshall LV; Balakumaran A; Benettaib B; Bhargava P; Bollard CM; Bolotin E; Bomken S; Buechner J; Burkhardt B; Caron H; Copland C; Demolis P; Egorov A; Farhan M; Zugmaier G; Gross T; Horton-Taylor D; Klapper W; Lesa G; Marcus R; Miles RR; Nottage K; Pacaud L; Ricafort R; Schrappe M; Sterba J; Vezan R; Weiner S; Kim SY; Reaman G; Vassal G
Eur J Cancer; 2019 Mar; 110():74-85. PubMed ID: 30772656
[TBL] [Abstract][Full Text] [Related]
13. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
[TBL] [Abstract][Full Text] [Related]
15. Strategies to facilitate adolescent access to medicines: Improving regulatory guidance.
Bucci-Rechtweg C; Siapkara A; An Haack Bonnet K; Corriol Rohou S; Haf Davies E; Dehlinger Kremer M; Gamalo M; Moreno C; Nelson RM; Thomas Turner R
Clin Trials; 2023 Feb; 20(1):13-21. PubMed ID: 36341541
[TBL] [Abstract][Full Text] [Related]
16. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
Vassal G; de Rojas T; Pearson ADJ
Lancet Child Adolesc Health; 2023 Mar; 7(3):214-222. PubMed ID: 36682367
[TBL] [Abstract][Full Text] [Related]
17. Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.
Moreno L; Pearson ADJ; Paoletti X; Jimenez I; Geoerger B; Kearns PR; Zwaan CM; Doz F; Baruchel A; Vormoor J; Casanova M; Pfister SM; Morland B; Vassal G;
Nat Rev Clin Oncol; 2017 Aug; 14(8):497-507. PubMed ID: 28508875
[TBL] [Abstract][Full Text] [Related]
18. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Moreno L; Caron H; Geoerger B; Eggert A; Schleiermacher G; Brock P; Valteau-Couanet D; Chesler L; Schulte JH; De Preter K; Molenaar J; Schramm A; Eilers M; Van Maerken T; Johnsen JI; Garrett M; George SL; Tweddle DA; Kogner P; Berthold F; Koster J; Barone G; Tucker ER; Marshall L; Herold R; Sterba J; Norga K; Vassal G; Pearson AD
Expert Opin Drug Discov; 2017 Aug; 12(8):801-811. PubMed ID: 28604107
[TBL] [Abstract][Full Text] [Related]
19. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
[TBL] [Abstract][Full Text] [Related]
20. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
